Nitric Oxide — The Key to the Heart You’ve Never Heard Of?

Aim of the study: It has been suggested that nitrate-rich beetroot juice (BRJ) reduces blood pressure (BP) in various populations. We aimed to investigate the effect of BRJ on BP in adults with hypertension according to the European Society of Hypertension Guidelines (clinical BP ≥ 140/≥ 90 mmHg), and whether BRJ can be considered as an addition to hypertension drug treatment, by conducting a meta-analysis of randomized controlled trials.

Results: Daily intake of 200–800 mg of nitrate from BRJ may reduce clinical systolic BP in people with hypertension, with no sign of tolerance developing. The certainty of the evidence is low, and the results should be interpreted with caution.

Aim of the study: Beetroot juice (BRJ) has become increasingly popular among athletes aiming to improve sports performance. BRJ contains high concentrations of nitrate, which can be converted into nitric oxide (NO) after consumption.

Results: Furthermore, consuming BRJ also affects oxygen delivery to skeletal muscles, muscle efficiency, tolerance, and endurance, and may therefore have a positive impact on sports performance. In addition to the benefits of BRJ consumption, there may also be potential health risks. Drinking BRJ may easily raise nitrate intake above the acceptable daily intake, which is known to stimulate the body's formation of N-nitroso compounds (NOCs), a class of compounds known to be carcinogenic and that may also cause several other adverse effects. Compared with studies on the benefits, the amount of data and literature on the negative effects of BRJ is rather limited and should be increased to allow a balanced risk assessment.

Aim of the study: To explain the mechanisms of nitric oxide (NO) production in humans and how lifestyle, drug therapy, and hygiene practices can reduce NO production. It also aims to show how functional nitric oxide nutrition can overcome these limitations to restore the body's own NO production and combat cardiovascular disease.

Results: Research over the past decade has revealed that inorganic nitrate and nitrite found naturally in green leafy vegetables and other vegetables such as beets can provide the human body with a source of bioactive nitric oxide. NO is one of the most important molecules produced within the cardiovascular system. It maintains normal blood pressure and prevents inflammation, immune dysfunction, and oxidative stress, which are hallmarks of cardiovascular disease. This pathway depends on the amount of inorganic nitrate and nitrite in the foods we eat, the presence of nitrate-reducing bacteria in the mouth, and sufficient stomach acid production. The idea that food can be medicine and medicine can be food has lost its place in the practice and implementation of modern medicine over the past century.

Aim of the study: The surprising discovery that the diatomic gas nitric oxide (NO) is generated by mammalian cells and regulates many physiological processes has continued to fascinate biologists for almost four decades. The biochemistry of NO is complex, and new insights into the control of NO biosynthesis and the mechanisms of signal transduction continue to emerge.

Results: The surprising discovery that the diatomic gas nitric oxide (NO) is generated by mammalian cells and regulates many physiological processes has continued to fascinate biologists for almost four decades. The biochemistry of NO is complex, and new insights into the control of NO biosynthesis and the mechanisms of signal transduction continue to emerge. NO is a key regulator of cardiovascular function, metabolism, neurotransmission, immunity, and more, and abnormal NO signaling is a central feature of many major disorders, including cardiovascular disease, diabetes, and cancer. Here, we discuss the basics of NO biology, emphasizing recent advances in the field, including new ways to increase NO bioactivity with therapeutic and nutritional implications.

Aim of the study: Nitric oxide (NO) from endothelial NO synthase contributes importantly to vascular homeostasis. Reduced NO production or increased scavenging under disease conditions involving oxidative stress contributes to endothelial dysfunction and NO deficiency.

Results: SIGNIFICANCE STATEMENT: After four decades of intensive research, questions remain about the transduction and control of nitric oxide (NO) synthase bioactivity. Here we discuss NO signaling in cardiovascular health and disease, highlighting new findings, such as the important role of red blood cells in cardiovascular NO homeostasis. Nonclassical signaling modes, such as the nitrate-nitrite-NO pathway, and therapeutic opportunities related to the NO system are discussed. Existing and potential pharmacological treatments and strategies, as well as dietary components that influence NO generation and signaling, are covered.

Aim of the study: Nitric oxide (NO) is a powerful mediator with biological activities such as widening blood vessels and preventing vascular smooth muscle cell proliferation, as well as regulating the function of heart cells. Thus, impaired production or reduced availability of NO makes the onset of various cardiovascular (CV) diseases more likely.

Results: Because of its ability to influence cell proliferation and the growth of new blood vessels, NO may be considered a treatment option for several CV diseases. Several clinical studies and trials have investigated NO-based treatments for systemic hypertension, atherosclerosis and/or the prevention of in-stent restenosis, coronary heart disease (CHD), pulmonary arterial hypertension (PAH), and heart failure (HF), although results for long-term treatment and the effective dose in selected patient groups have been mixed. Tadalafil, sildenafil, and cinaguat were evaluated for the treatment of PAH, while vericiguat was studied in patients with HF and reduced ejection fraction. In addition, supplementation with hydrogen sulfide, tetrahydrobiopterin, and nitrite/nitrate has shown beneficial effects on blood vessels.

Aim of the study: Nitric oxide (NO) has been recognized as an important factor in the cardiovascular system. As a signaling molecule in the cardiovascular system, NO can relax blood vessels, lower blood pressure, and prevent platelet aggregation.

Results: Growing evidence suggests that NO can regulate mitochondria, affecting mitochondrial function and cellular activity, which in turn influences the onset and progression of disease. However, there is no comprehensive understanding of how NO regulates mitochondrial function in the cardiovascular system. This review aims to summarize how nitric oxide regulates mitochondrial function in cardiovascular diseases, as well as the many complex roles of NO in the cardiovascular system. Understanding how NO affects mitochondrial function can provide new insights into the prevention and treatment of cardiovascular diseases.

Aim of the study: Nitric oxide (NO) is a molecule recognized as a crucial regulator of vascular disease. NO has several effects inside cells that lead to blood vessel relaxation, endothelial regeneration, inhibition of leukocyte movement toward chemical signals, and platelet adhesion.

Results: It plays an important role in the development of many cardiovascular diseases, including atherosclerosis, intimal hyperplasia, and aneurysmal disease. In addition, NO has been used as a treatment tool for conditions ranging from recurrent stenosis to the prevention of blood clots. Many commonly used medications work therapeutically through NO production. This review highlights the biological properties of NO in blood vessels, its role in the development of cardiovascular diseases, and its potential therapeutic uses.

Aim of the study: Nitric oxide produced by three different forms of nitric oxide synthase (NOS), which are widely expressed in almost all types of vascular cells, is produced mainly by the endothelial form (eNOS) in endothelial cells, where it plays a crucial role in regulating vascular tone and structure. It also has an anti-inflammatory effect, inhibits platelet adhesion and aggregation, and prevents smooth muscle cells from multiplying and migrating.

Results: Nitric oxide produced by three different forms of nitric oxide synthase (NOS), which are widely expressed in almost all types of vascular cells, is produced mainly by the endothelial form (eNOS) in endothelial cells, where it plays a crucial role in regulating vascular tone and structure. It also has an anti-inflammatory effect, inhibits platelet adhesion and aggregation, and prevents smooth muscle cells from multiplying and migrating. Several lines of evidence link endothelial dysfunction, characterized by reduced nitric oxide availability, with the development of many conditions, such as heart failure, hypertension, diabetes, and atherosclerosis. This review focuses on nitric oxide-dependent endothelial dysfunction in cardiovascular diseases, its clinical detection and significance, possible mechanisms involved in disease development, and potential treatments.

Aim of the study: Third-generation β-blockers have important additional properties beyond blocking β-adrenoceptors. Among them, nebivolol activates nitric oxide synthase (NOS).

Results: Nebivolol and carvedilol preserve NOS activity by reducing asymmetric dimethylarginine (ADMA) and increase nitric oxide (NO) availability because of their antioxidant properties. In the treatment of hypertension and chronic heart failure, these third-generation β-blockers have distinct advantages resulting from their NO-dependent effects (vasodilation, reduced cell growth, and heart protection), which may lead to better clinical outcomes than those achieved with conventional β-blockers. Impaired NOS activity and reduced NO availability are common triggers of cardiovascular dysfunction. Thus, because of their NO-mediated actions, the newer generation of β-blockers may find wider clinical use in treating cardiovascular diseases.